Stran je namenjena samo zdravstvenim delavcem s prebivališčem v Republiki Sloveniji.

Search

Menu

Close

PrijavaOdjava
Naša zdravilaTerapevtska področjaMedia CenterMedia CenterDogodkiGradivaVideo vsebinePovežimo sePovežimo seKontaktirajte nasMedicinske informacije družbe Pfizer

Menu

Close

About Prevenar 20™ at a Glance Serotype Coverage Pneumococcal Disease Clinical Programme RecommendationsPractical Use Resources
Pneumococcal infections remain a leading cause of death in children under 5 years of age worldwide1,2Major manifestations of infection with Streptococcus pneumoniae1

Invasive pneumococcal disease (IPD)
Includes meningitis, bacteraemia/sepsis
Approximately 300,000 deaths among children <5 years of age were estimated to be caused by pneumococcal infections in 2015. Case fatality rates from IPD in children can be high, ranging up to 20% for septicaemia and 50% for meningitis in certain parts of the world.3

Pneumonia
Community-acquired pneumonia (CAP) is a leading cause of death worldwide in children under 5 years of age.4,5

Otitis media (OM)
S. pneumoniae accounts for 30% to 50% of all OM cases worldwide and is the most likely pathogen to be associated with recurrent infections and postinfectious complications characteristic of complicated OM.6

Prevenar 20™ helps prevent pneumococcal disease caused by the 20 serotypes in the vaccine, providing the broadest serotype coverage available in a pneumococcal conjugate vaccine.7-9
Explore the broadest serotype coverage available for babies7-9
LoadingReferences:Gierke R, Wodi AP, Kobayashi M. Pneumococcal disease. In: Hall E, Wodi AP, Hamborsky J, Morelli V, Schillie S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 14th ed. Centers for Disease Control and Prevention; 2021:chap 17. Accessed March 29, 2023. https://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html.UNICEF. Childhood diseases. Accessed February 15, 2022. https://www.unicef.org/health/childhood-diseases.World Health Organization. Weekly epidemiological record. Vol 8. 2019;94:85-104.Nascimento-Carvalho CM. Community-acquired pneumonia among children: the latest evidence for an updated management. J Pediatr (Rio J). 2020;96(suppl 1):29-38.Popovsky EY, Florin TA. Community-acquired pneumonia in childhood. Encyclopedia of Respiratory Medicine. 2nd ed. Elsevier; 2022:119-131.Bergenfelz C, Hakansson AP. Streptococcus pneumoniae otitis media pathogenesis and how it informs our understanding of vaccine strategies. Curr Otorhinolaryngol Rep. 2017;5(2):115-124.Prevenar 20™ (Pneumococcal 20-valent Conjugate Vaccine). Summary of Product Characteristics. Wyeth Pharmaceuticals LLC; 2024.Prevenar 13® (Pneumococcal 13-valent Conjugate Vaccine). Summary of Product Characteristics. Wyeth Pharmaceuticals LLC; 2014.Vaxneuvance™ (Pneumococcal 15-valent Conjugate Vaccine). Summary of Product Characteristics. Merck Sharp & Dohme Corp.; 2023.Centers for Disease Control and Prevention. ACIP updates: recommendations for the use of 20-valent pneumococcal conjugate vaccine in children—United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(39):1072. https://stacks.cdc.gov/view/cdc/133252.AboutQuick links card The broadest serotype coverage for babies in a pneumococcal conjugate vaccine7-9 Learn more LoadingQuick links card [Local body] recommends Prevenar 20™ for routine infant vaccination10 Learn more Loading
PP-PNR-GLB-0425 March 2024
PfizerPro računPfizerPro račun

Za dostop do dodatnih gradiv, vsebin in prejemanje sporočil o zdravilih in cepivih družbe Pfizer

VpisRegistracijaRačunOdjava

To spletno mesto je namenjeno samo zdravstvenim delavcem s prebivališčem v Republiki Sloveniji. Če se uvrščate med širšo javnost in bi želeli dostopati do informacij o določenem zdravilu, se, prosimo, obrnite na vašega zdravnika ali farmacevta.

 

To spletno stran vam ponuja Pfizer, podružnica Ljubljana.

 

Avtorske pravice 2022 Pfizer, podružnica Ljubljana. Vse pravice pridržane.


Davčna številka: SI 17966086

PP-UNP-SVN-0142, datum priprave: september 2023
Zapuščate PfizerPro
​
Zapuščate spletno mesto, ki ga upravlja Pfizer. Povezave do vseh zunanjih spletnih mest so na voljo kot vir za naše obiskovalce. Pfizer ne prevzema odgovornosti za vsebino spletnih mest, ki niso v lasti in upravljanju družbe Pfizer.
 
PP-UNP-SVN-0142
datum priprave: september 2023
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​ Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​